Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The macrolides: erythromycin, clarithromycin, and azithromycin.

S Alvarez-Elcoro1, M J Enzler

  • 1Division of Infectious Diseases and Internal Medicine, Mayo Clinic Jacksonville, Florida, USA.

Mayo Clinic Proceedings
|June 23, 1999
PubMed
Summary

New macrolides like azithromycin and clarithromycin offer improved stability and broader spectrum against infections such as Mycobacterium avium complex (MAC). However, increasing macrolide resistance is a growing concern for future antimicrobial effectiveness.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erysipelothrix rhusiopathiae bloodstream infection - A 22-year experience at Mayo Clinic, Minnesota.

Zoonoses and public health·2017
Same author

Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2001
Same author

Use of lambda phage DNA as a hybrid internal control in a PCR-enzyme immunoassay to detect Chlamydia pneumoniae.

Journal of clinical microbiology·1998
Same author

Vibrio vulnificus skin lesion.

Digestive diseases (Basel, Switzerland)·1995
Same author

In vitro and in vivo studies of streptomycin-resistant, penicillin-susceptible streptococci from patients with infective endocarditis.

The Journal of infectious diseases·1987
Same author

Community-acquired febrile illness in patients with prosthetic heart valves.

Southern medical journal·1985

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Erythromycin has been a primary macrolide antibiotic, but newer agents offer distinct advantages.
  • Azithromycin and clarithromycin represent advancements in macrolide antibiotic therapy.

Purpose of the Study:

  • To compare the chemical stability, antimicrobial spectrum, pharmacokinetics, and clinical applications of azithromycin and clarithromycin versus erythromycin.
  • To highlight the efficacy of azithromycin and clarithromycin in treating specific infections, including Mycobacterium avium complex (MAC) and atypical respiratory pathogens.
  • To address the emerging issue of macrolide resistance and its potential impact on future treatment strategies.

Main Methods:

  • Comparative analysis of chemical stability and antimicrobial spectrum.

Related Experiment Videos

  • Pharmacokinetic profiling to assess dosing schedules and tissue penetration.
  • Review of clinical data regarding efficacy in MAC prophylaxis and treatment, respiratory tract infections, skin/soft tissue infections, community-acquired pneumonia, and pelvic inflammatory diseases.
  • Assessment of drug-drug interactions and pediatric tolerance.

    • Main Results:

    • Azithromycin and clarithromycin exhibit enhanced chemical stability and broader antimicrobial activity compared to erythromycin, particularly against MAC, H. influenzae, and C. trachomatis.
    • Both agents demonstrate excellent activity against atypical respiratory pathogens (C. pneumoniae, Mycoplasma) and Legionella species.
    • Pharmacokinetics allow for shorter dosing schedules; both are effective for MAC prophylaxis in AIDS patients, with azithromycin preferred due to fewer interactions.
    • Clarithromycin is crucial for treating active MAC disease; azithromycin offers advantages in pediatric compliance.
    • Increasing macrolide resistance in S. pneumoniae, group A streptococci, and H. influenzae is a significant concern.

    Conclusions:

    • Azithromycin and clarithromycin are valuable macrolide antibiotics with improved profiles over erythromycin, offering effective treatment options for various infections.
    • Their pharmacokinetic properties and efficacy in specific patient populations (e.g., AIDS, children) enhance therapeutic utility.
    • The rising prevalence of macrolide resistance poses a threat to the long-term clinical effectiveness of this antibiotic class.